Skip to main content

Table 1 Experimental validation of predicted anti-malarial single agent compounds

From: A systematic and prospectively validated approach for identifying synergistic drug combinations against malaria

Compound

Class

3D7

Class

DD2

Class

HB3

AC50

3D7

AC50

DD2

AC50

HB3

Average AC50

CHR

− 1.1

− 1.1

− 1.1

0.0119

0.0106

0.0106

0.011

FUL

− 1.1

− 1.1

− 1.1

0.0335

0.0335

0.1332

0.0667

API

− 1.1

− 1.1

− 1.1

0.0749

0.0841

0.0749

0.078

ING

− 1.1

− 1.1

− 1.1

1.3324

1.495

1.495

1.4408

MON

− 2.1

− 2.1

− 2.3

1.4956

1.0588

1.8828

1.4791

RAL

− 1.1

− 1.1

− 2.1

0.7493

0.3347

4.7277

1.9372

TAC

− 1.1

− 1.1

− 1.1

1.8821

3.7553

1.6774

2.4383

CHE

1.3

− 2.3

1.3

0.0266

10.5839

0.0011

3.5372

JX4

− 1.1

− 1.1

− 2.1

0.7493

0.0595

10.5839

3.7976

HYD

− 1.1

− 1.1

− 2.1

2.6586

1.6774

11.8754

5.4038

THI

− 2.1

− 2.1

− 2.1

10.5839

14.9502

14.9502

13.4948

MEG

− 2.1

− 1.1

− 2.1

14.9502

1.8821

23.6945

13.5089

PI8

− 2.3

− 2.1

− 2.1

13.3244

11.8754

16.7744

13.9914

KIN

− 2.1

− 2.1

− 2.1

13.3244

21.1177

16.7744

17.0722

  1. The fitted AC50 values (µM) for the single drugs as well as classes of activity are listed. AC50 indicates 50% maximal response (for inhibition or agonism) and is calculated by fitting a 4-parameter logistic model to the concentration, response data. Curve classes are defined in Additional file 2: Figure S1
  2. Classes that are identified as −1.1 are highlighted in italics as it signifies complete curve as well as high efficacy